The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer ...

Blocking proteins that cause cancer cells to mutate and resist treatment could significantly improve outcomes for some ...

The Small Cell Lung Cancer market report also offers comprehensive insights into the Small Cell Lung Cancer market size, ...

RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment ...

Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

RxDx Device for non-small cell lung cancer has received Breakthrough Device Designation from the U.S. Food and Drug ...

Imdelltra (tarlatamab-dlle) has shown statistically significant and clinically meaningful improvement in overall survival compared to local standard-of-care chemotherapy among patients with small cell ...

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with ...

YAP, a protein known to help cancer cells survive treatment, behaves very differently in cell culture models depending on how they are grown in the lab, highlighting the importance of mimicking tumour ...

The global lung cancer therapeutics market is on a robust growth trajectory, poised to witness a significant transformation over the next decade. According to recent market projections, the industry ...